Q3 2024 Earnings Summary
- Tandem Diabetes Care achieved record quarterly sales in both U.S. and international markets, with Q3 2024 sales of $243 million marking the highest in the company's history, indicating strong market demand and operational performance.
- The company is expanding its product portfolio, receiving positive feedback on new products like the Tandem Mobi, and has signed its first pharmacy channel agreement, which could enhance market access, reduce patient out-of-pocket costs, and contribute to future growth.
- Tandem is poised to expand into the insulin-dependent type 2 diabetes market, having completed the pivotal trial for expanding the indication of their Control-IQ technology, aiming to tap into a large and underpenetrated market segment and expecting regulatory submission to the FDA by the end of the year.
- Management's 2025 guidance remains uncertain and potentially conservative, as they emphasize starting with predictable revenue streams and balancing risks and opportunities. Despite multiple growth drivers, they are hesitant to provide specifics or commit to higher growth rates. ,
- Order pull-forwards have inflated current quarter results, which may dampen future performance. Specifically, the Q3 sales benefited from approximately $5 million in orders received earlier than anticipated in the fourth quarter. This could lead to a sequential step-down in OUS sales in Q4. ,
- Potential supply chain risks due to tariffs and geopolitical uncertainties could impact costs and operations. Management acknowledges that their supply chain crosses into Asian countries that could be problematic under new tariff policies, introducing potential cost pressures.
| Metric | YoY Change | Reason |
|---|---|---|
Total Revenue | +31% (from $185.62M in Q3 2023 to $243.97M in Q3 2024) | Total revenue increased significantly driven by strong overall demand, with improvements in both pump and supplies segments. This recovery reflects a rebound from previous challenges as product launches and market conditions enabled stronger sales performance. |
Pump Revenue | +30% (from $88.0M to $114.8M) | Pump revenue growth is attributed to higher pump shipments and improved market acceptance, supported by new product introductions that built on prior lower figures. The increase helped drive domestic and international sales, reflecting a recovery from earlier subdued performance. |
Supplies and Other Revenue | +21% (from $105.8M to $128.1M) | Supplies revenue improved due to an expanded installed customer base and improved pricing, offsetting previous periods where growth was limited. Continued momentum in the U.S. and stabilization in international markets contributed to this robust YoY increase. |
Tandem Choice Program | Turnaround from –$8.2M to +$1.0M | The Tandem Choice Program shifted positively as deferred revenue from previous periods was recognized following the program’s evolution. The significant turnaround reflects the conclusion of deferrals and a transition to revenue recognition, reversing the prior negative balance. |
U.S. Revenue | +32% (from $130.20M to $171.65M) | U.S. revenue surged owing to higher pump shipments, increased supplies sales, and improved pricing strategies. The growth indicates a strong domestic market rebound compared to earlier subdued performance, with enhanced customer adoption and favorable market conditions. |
Revenue Outside the U.S. | +30% (from $55.40M to $72.32M) | International revenue climbed as operational efficiencies improved post-European distribution center disruptions. Enhanced distributor ordering and recovery from previous logistical challenges contributed to the robust YoY growth. |
Operating Income | Loss narrowed by 17% (from –$31.55M to –$26.09M) | Operating performance improved due to higher sales driving increased gross profit combined with better cost management. While challenges remained, improved revenue mix and reduced one-time charges contributed to a relative reduction in operating losses compared to prior levels. |
Net Income | Loss reduced by ~30% (from –$32.96M to –$23.25M) | Net income showed significant improvement through higher sales and increased gross profit, despite ongoing losses. The better cost control and improved operating income narrowed the net loss, marking a notable recovery from the previous period's lower performance. |
EPS (Basic & Diluted) | Improved from –$0.50 to –$0.35 | EPS improvement resulted from a smaller net loss driven by increased sales and margin recovery, partially offset by modest share dilution. This reflects the company’s progress in addressing prior challenges and moving towards a healthier profitability profile. |
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Worldwide Sales | Q3 2024 | no prior guidance | $222 million to $225 million, 15%–16% YoY | no prior guidance |
U.S. Sales | Q3 2024 | no prior guidance | $162 million to $165 million | no prior guidance |
Outside the U.S. (OUS) Sales | Q3 2024 | no prior guidance | Approximately $60 million | no prior guidance |
Free Cash Flow | Q3 2024 | no prior guidance | $22 million positive | no prior guidance |
Worldwide Sales | FY 2024 | $885 million to $892 million, 15% YoY | $903 million to $910 million, 17%–18% YoY | raised |
U.S. Sales | FY 2024 | $640 million to $645 million | $645 million to $650 million | raised |
Outside the U.S. (OUS) Sales | FY 2024 | $245 million to $247 million | $258 million to $260 million | raised |
Gross Margin | FY 2024 | 51% | 51% | no change |
Adjusted EBITDA | FY 2024 | Breakeven | Breakeven | no change |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Record Sales and Strong Market Demand | Emphasized in Q1, Q2, and Q4 with record‐level sales, high pump shipments, and strong year‐over‐year growth in both U.S. and international markets | Q3 2024 reported the highest quarterly sales in history at $243 million with strong demand in both U.S. and OUS, reflecting robust new customer starts and conversion from MDI users | Consistent robust performance with incremental improvements across regions. |
Expansion of Product Portfolio | Consistently highlighted in Q1, Q2, and Q4 through the launch of the Tandem Mobi pump, its integration with technologies (e.g., Dexcom G6/G7, FreeStyle Libre), and positive early user feedback | Q3 2024 emphasized the Mobi pump’s enhanced features, upcoming integrations, new cost advantages, and scalability initiatives | Stable focus on innovation with expanded functionalities and improved cost profiles. |
Growth in the Insulin Pump Market and MDI Conversions | Detailed in Q1, Q2, and Q4 with commentary on market expansion, significant conversion of MDI users, and a shift towards new customer adoption | Q3 2024 reiterated strong market growth with more than half of pump shipments attributed to new MDI conversions and increasing overall pump adoption | Sustained expansion with continued emphasis on converting MDI users. |
Emerging Focus on Insulin-Dependent T2D Market | Discussed in Q1, Q2, and Q4 with progress on clinical trials, regulatory submission plans, and recognition of a large untapped market opportunity | Q3 2024 reinforced the strategic focus with completed pivotal trials and plans to file the regulatory submission by year‑end | Steady commitment with an increasing regulatory and market development focus. |
Guidance Uncertainty and Cautious Forward-Looking Growth Forecasts | Addressed across Q1, Q2, and Q4 by emphasizing reliance on predictable revenue (supply and renewals) and a cautious approach to new product trends | Q3 2024 maintained a cautious forecast, underlining predictable revenue streams and a conservative approach despite strong recent performance | Consistent cautious sentiment with forecasts anchored in proven revenue streams. |
Newly Highlighted Supply Chain Risks Driven by Tariffs and Geopolitical Uncertainties | Not mentioned in Q1, Q2, or Q4 | Q3 2024 introduced concerns about tariffs and geopolitical uncertainties impacting the supply chain, with emphasis on the company’s flexibility in managing these risks | New topic emerging in Q3, reflecting elevated global risk awareness. |
Margin Pressures and Financial Performance Challenges Linked to New Product Rollouts | Discussed in Q1, Q2, and Q4 regarding Mobi-related pressure, cost trade-offs, and expectations for margin improvement as volume scales | Q3 2024 reported a gross margin of 51% and noted ongoing margin pressure from the Mobi rollout, with improvements anticipated as production scales in 2025 | Ongoing concern with consistent short-term pressures expected to ease with scaling. |
Increased Competitive Pressures in Domestic and International Markets | Addressed in Q1 and Q4 (with some mentions in Q2) citing intensifying competition and the need for differentiation through technology and market strategies | Q3 2024 did not provide specific commentary on increased competitive pressures | Less emphasized in Q3, suggesting either stabilization or a lower prioritization in current discussions. |
Order Pull-Forward Effects Influencing Sequential Performance | Not mentioned in Q1, Q2, or Q4 | Q3 2024 highlighted timing shifts in U.S. sales and order pull-forward effects in OUS markets contributing to sequential gains | New emerging concern, now recognized as a factor in sequential performance. |
Shift in Sentiment Regarding Long-Term Impact and Transparency Around New Product Launches | Q1 and Q4 conveyed positive long-term outlooks for new product launches with cautious transparency regarding specific timelines | Q3 2024 did not provide specific commentary on this shift | Reduced explicit emphasis in Q3, though earlier positive long-term sentiment likely persists. |
Pricing Improvements/ASPs | Consistently emphasized in Q1, Q2, and Q4 through improved U.S. pricing, normalized OUS ASPs, and favorable revenue mix contributing to margins | Q3 2024 reiterated the benefit of pricing improvements and a favorable mix, supporting both sales and margins | Stable and consistently positive contributor to financial performance. |
Customer Retention/Renewals | Highlighted in Q1, Q2, and Q4 with strong renewal growth, high retention rates, and significant recurring revenue from warranty expirations | Q3 2024 reported the highest-ever renewal rates and robust recurring revenue performance, especially in the U.S., with future potential internationally | Continues to be a bright spot, reinforcing customer loyalty and predictable revenue. |
-
2025 Growth Outlook
Q: Why would growth slow in 2025 versus 2024?
A: Leigh explained that despite exciting upcoming catalysts like a full year of Mobi, type 2 indication in the U.S., and Libre integration, the initial 2025 guidance will be conservative. They focus on predictable revenue streams like supply sales and renewals. They prefer to see sustainable trends before factoring new growth drivers into expectations. ( ) -
Q4 Guidance and Margins
Q: Why didn't full-year guidance increase more given the Q3 beat?
A: Leigh stated that they raised guidance by the amount of the Q3 beat. The Q4 outlook considers seasonal dynamics, with the quarter typically representing just under 30% of annual U.S. revenue. OUS outperformance was due to a $5 million timing shift from Q4 to Q3. Margins were impacted by Mobi scaling and higher OUS mix but are expected to improve as Mobi achieves scale. ( ) -
Pharmacy Strategy Impact
Q: How will the pharmacy contract affect your business?
A: Leigh and John celebrated executing their first pharmacy contract, an important step in their strategy. While they couldn't share specifics, the contract meets criteria of lowering patient out-of-pocket costs and being economically favorable. They are pursuing additional contracts and view pharmacy access as a multi-year initiative to enhance affordability and drive growth. ( , , ) -
Type 2 Opportunity
Q: Can you grow type 2 adoption before label expansion?
A: John noted that type 2 users currently represent about 5–10% of new starts, with around 30,000 type 2 users on Control-IQ off-label. They expect uptake to remain steady until they can actively market post-approval. After FDA approval, they aim to increase penetration to over 25% of the insulin-intensive type 2 market. They are preparing to submit clinical data and anticipate a swift approval based on prior FDA familiarity with Control-IQ. ( , ) -
Mobi Pump Uptake
Q: Is Mobi adoption meeting expectations?
A: John expressed excitement about Mobi's positive reception, noting it's driving pump growth not seen in a while. They are achieving objectives, with Mobi contributing to year-over-year growth in new pumps and increased MDI conversions for two consecutive quarters. Former patch pump users are switching to Mobi due to its size and Control-IQ performance. ( , , ) -
Adjusted EBITDA Margins
Q: How should we view margin trajectory going forward?
A: Leigh explained this is a transition year with Mobi scaling up. Mobi will contribute to long-term gross margin improvement, offering 10–15% lower manufacturing costs for pumps and 20% for cartridges compared to t:slim. As volumes increase and Mobi scales, margins are expected to improve. Market access initiatives like the pharmacy channel will also enhance margins over time. ( ) -
Renewals, Including OUS
Q: Can you update on renewals, especially OUS opportunities?
A: Leigh reported that renewals continue to be a bright spot, with high renewal rates in the U.S. OUS renewal opportunities will become more meaningful starting in 2025, as customers from initial launches in 2018–2020 come up for renewal. They are partnering with distributors to apply best practices and expect to be just as successful OUS as in the U.S. ( , ) -
Market Growth and Share
Q: Is the pump market accelerating, and how is Tandem positioned?
A: John believes the market is growing this year without last year's disruptions from multiple product launches. He expects continued growth driven by innovation, new products, and new indications. With challenges like pharmacy access and new product introductions being addressed, he is confident that Tandem can grow with the market and benefit from tailwinds in 2025 and beyond. ( , ) -
Tariff Impacts
Q: Are tariffs a concern for your supply chain?
A: John acknowledged that potential tariffs are on their radar. While they source components internationally, they have a flexible supply chain that allows them to mitigate impacts. They are monitoring the situation closely and can adjust their operations as more specifics become available. ( ) -
Supply Revenue Strength
Q: What drove the strong supply revenue this quarter?
A: Leigh attributed the U.S. supply revenue strength to a timing shift from Q2 to Q3 and favorable pricing. OUS supply revenue benefited from approximately $5 million in orders that occurred in Q3 instead of Q4 due to timing shifts. These factors collectively led to stronger supply sales in the quarter. ( )